癌度医学临床招募资讯微信群（点击）我们对于恶性肿瘤的靶向药治疗效果存在误区，比如认为将靶向药使用之后应该是立竿见影见效才对，事实上任何的靶向药只有部分患者有效果。我们还会认为靶向药可以一直持续用下去，事实上靶向药会存在耐药的问题（这就是中位无进展生存 ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

At AACR 2025, Lunit will showcase its latest AI-driven approach to predicting EGFR mutations in NSCLC—in collaboration with ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

EGFR mutation testing plays a crucial role in determining the best course of treatment for patients with NSCLC, yet many patients remain untested due to logistical and resource constraints ...

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...